Literature DB >> 77019

Immunogenicity of the envelope glycoprotein of avian sarcoma virus.

M S Halpern, R R Friis.   

Abstract

The expression of type E-specific glycoprotein in chick-helper factor-positive [chf(+)] chickens is not restricted to a certain stage of embryogenesis but persists in postembryonic life. This finding prompted an investigation of the immunogenicity of the viral envelope glycoprotein of exogenous avian sarcoma virus in chf(+) and chf(-) chickens. Sensitization of both classes of chickens resulted in the induction of detectable antibody reactivity to determinants of the glycoprotein that were type-specific as well as group-specific. Because group-specific determinants are present on type E-specific glycoprotein, these results link immunity to exogenous viral envelope glycoprotein in chf(+) chickens with autoreactivity. A model is proposed to rationalize the induction of reactivity in this system.

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 77019      PMCID： PMC392462          DOI： 10.1073/pnas.75.4.1962

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN： 0027-8424            Impact factor:   11.205


  11 in total

1.  Expression of endogenous ALV antigens and susceptibility to subgroup E ALV in three strains of chickens (endogenous avian C-type virus).

Authors:  H L Robinson; W F Lamoreux
Journal:  Virology       Date:  1976-01       Impact factor: 3.616

2.  Presence of antigen common to avian tumor viral envelope antigen in normal chick embryo cells.

Authors:  H Hanafusa; T Aoki; S Kawai; T Miyamoto; R E Wilsnack
Journal:  Virology       Date:  1973-11       Impact factor: 3.616

Review 3.  Virion and tumor cell antigens of C-type rna tumor viruses.

Authors:  H Bauer
Journal:  Adv Cancer Res       Date:  1974       Impact factor: 6.242

4.  A cell-associated factor essential for formation of an infectious form of Rous sarcoma virus.

Authors:  H Hanafusa; T Miyamoto; T Hanafusa
Journal:  Proc Natl Acad Sci U S A       Date:  1970-06       Impact factor: 11.205

5.  Kinetic differences in unresponsiveness of thymus and bone marrow cells.

Authors:  J M Chiller; G S Habicht; W O Weigle
Journal:  Science       Date:  1971-02-26       Impact factor: 47.728

6.  An avian leukosis virus related to RSV(O): properties and evidence for helper activity.

Authors:  P K Vogt; R R Friis
Journal:  Virology       Date:  1971-01       Impact factor: 3.616

7.  Radioimmunoassay for the envelope glycoprotein of subgroup E avian leukosis-sarcoma viruses.

Authors:  E J Smith; L B Crittenden; A K Whitson
Journal:  Virology       Date:  1978-02       Impact factor: 3.616

8.  Isolation of the major viral glycoprotein and a putative precursor from cells transformed by avian sarcoma viruses.

Authors:  M S Halpern; D P Bolognesi; L J Lewandowski
Journal:  Proc Natl Acad Sci U S A       Date:  1974-06       Impact factor: 11.205

9.  Hapten-specific stimulation of secondary B cells independent of T cells.

Authors:  N R Klinman; R A Doughty
Journal:  J Exp Med       Date:  1973-08-01       Impact factor: 14.307

10.  Development of chicken lymphoid system. II. Synthesis of primordial immunoglobulin M by the bursa cells of chick embryo.

Authors:  Y S Choi; R A Good
Journal:  J Exp Med       Date:  1972-07-01       Impact factor: 14.307
View more
  3 in total

1.  Antigenic determinants specific to the envelope glycoprotein of exogenous avian tumor viruses.

Authors:  S C Marini; R R Friis; M S Helpern
Journal:  J Virol       Date:  1979-02       Impact factor: 5.103

2.  Embryonic infection with the endogenous avian leukosis virus Rous-associated virus-0 alters responses to exogenous avian leukosis virus infection.

Authors:  L B Crittenden; S McMahon; M S Halpern; A M Fadly
Journal:  J Virol       Date:  1987-03       Impact factor: 5.103

3.  Host Susceptibility to endogenous viruses: defective, glycoprotein-expressing proviruses interfere with infections.

Authors:  H L Robinson; S M Astrin; A M Senior; F H Salazar
Journal:  J Virol       Date:  1981-12       Impact factor: 5.103
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.